FindTrial
Sign In

THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY FROM THE NORTHEN ITALY LEUKEMIA GROUP (NILG)

THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY FROM THE NORTHEN ITALY LEUKEMIA GROUP (NILG)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002280-24-IT
Enrollment
Unknown
Registered
2004-09-17
Start date
2004-07-26
Completion date
Unknown
Last updated
2012-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HYPEREOSINOPHILIC SYNDROME (HES, CEL, CIH) MedDRA version: 6.1 Level: HLGT Classification code 10024324

Interventions

Trade Name: GLIVEC*120CPS 100MG Product Name: imatinib Pharmaceutical Form: Capsule, hard INN or Proposed INN: Imatinib Current Sponsor code: NILG-HES 1-03 Concentration unit: mg milligram(s) Conce

Sponsors

AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026